Iressa, a new oral drug for lung cancer
February 2004
Health Canada will allow the use of Iressa, a new oral drug for lung cancer...under a conditional approval.
Iressa (gefitinib) is an "epidermal growth factor inhibitor."
It will be reserved for patients whose cancer progresses despite standard chemotherapy.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter Canada includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 200+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive